EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 157 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $81,436 | -15.9% | 5,164 | +3.7% | 0.00% | 0.0% |
Q2 2023 | $96,811 | -39.0% | 4,980 | -11.0% | 0.00% | 0.0% |
Q1 2023 | $158,787 | -2.5% | 5,597 | +0.4% | 0.00% | 0.0% |
Q4 2022 | $162,899 | +7.9% | 5,573 | -2.2% | 0.00% | 0.0% |
Q3 2022 | $151,000 | -40.1% | 5,700 | +0.4% | 0.00% | -50.0% |
Q2 2022 | $252,000 | -22.2% | 5,678 | -13.3% | 0.00% | 0.0% |
Q1 2022 | $324,000 | -8.5% | 6,546 | -5.8% | 0.00% | 0.0% |
Q4 2021 | $354,000 | -12.8% | 6,949 | -4.6% | 0.00% | 0.0% |
Q3 2021 | $406,000 | +25.7% | 7,284 | -3.5% | 0.00% | +100.0% |
Q2 2021 | $323,000 | +10.2% | 7,548 | +7.6% | 0.00% | 0.0% |
Q1 2021 | $293,000 | -11.5% | 7,015 | -1.3% | 0.00% | 0.0% |
Q4 2020 | $331,000 | +1.8% | 7,104 | -7.0% | 0.00% | -50.0% |
Q3 2020 | $325,000 | -11.2% | 7,639 | +0.0% | 0.00% | 0.0% |
Q2 2020 | $366,000 | +24.9% | 7,637 | +20.1% | 0.00% | 0.0% |
Q1 2020 | $293,000 | -26.9% | 6,360 | -4.7% | 0.00% | 0.0% |
Q4 2019 | $401,000 | +3.4% | 6,672 | -2.8% | 0.00% | 0.0% |
Q3 2019 | $388,000 | -1.5% | 6,862 | -3.0% | 0.00% | 0.0% |
Q2 2019 | $394,000 | -1.7% | 7,074 | -11.0% | 0.00% | 0.0% |
Q1 2019 | $401,000 | +20.8% | 7,952 | -3.6% | 0.00% | +100.0% |
Q4 2018 | $332,000 | -42.8% | 8,250 | -1.4% | 0.00% | -50.0% |
Q3 2018 | $580,000 | -1.4% | 8,366 | +7.6% | 0.00% | 0.0% |
Q2 2018 | $588,000 | +117.0% | 7,772 | +51.2% | 0.00% | +100.0% |
Q1 2018 | $271,000 | -21.2% | 5,139 | -20.1% | 0.00% | 0.0% |
Q4 2017 | $344,000 | -12.0% | 6,431 | -2.0% | 0.00% | 0.0% |
Q3 2017 | $391,000 | -18.9% | 6,562 | +7.3% | 0.00% | -50.0% |
Q2 2017 | $482,000 | +6.6% | 6,116 | +12.2% | 0.00% | 0.0% |
Q1 2017 | $452,000 | -10.0% | 5,451 | -13.9% | 0.00% | 0.0% |
Q4 2016 | $502,000 | -99.9% | 6,332 | -1.6% | 0.00% | 0.0% |
Q3 2016 | $450,520,000 | +127.9% | 6,436 | +26.3% | 0.00% | +100.0% |
Q2 2016 | $197,713,000 | -13.3% | 5,097 | -9.4% | 0.00% | 0.0% |
Q1 2016 | $228,000,000 | -54.3% | 5,625 | 0.0% | 0.00% | -50.0% |
Q4 2015 | $499,000,000 | +119564.3% | 5,625 | -0.2% | 0.00% | 0.0% |
Q3 2015 | $417,000 | -99.9% | 5,634 | +12.1% | 0.00% | 0.0% |
Q2 2015 | $406,564,000 | – | 5,028 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |